COVID-19Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Key words
Ruxolitinib
COVID-19
cytokine storm
efficacy
safety
randomized controlled trial
Abbreviations used
COVID-19
Coronavirus disease 2019
CT
Computed tomography
D
Day
ICU
Intensive care unit
IQR
Interquartile range
JAK
Janus-associated kinase
MIP-1α
Macrophage inflammatory protein 1α
MIP-1β
Macrophage inflammatory protein 1β
SARS
Severe acute respiratory syndrome
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SoC
Standard-of-care
VEGF
Vascular endothelial growth factor
Cited by (0)
This work was supported by the Emergency Research Project of Tongji Hospital (to J.Z.), Emergency Research Project of Tongji Hospital of Huazhong University of Science and Technology (grant no. 2020kfyXGYJ045 to J.Z.), and Emergency Research Project of Hubei province (grant no. 2020FCA006 to W.W.). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.
© 2020 American Academy of Allergy, Asthma & Immunology